According to our new research study on “Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 –Country Analysis – by Type, Indication, Application, and End User,” the cell and gene therapy manufacturing services market size is expected to grow from US$ 7,581.97 million in 2022 to US$ 26,724.90 million by 2030; it is estimated to register a CAGR of 17.1% during 2022–2030.
Key factors driving the cell and gene therapy manufacturing services market growth include increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing.
Based on type, the cell and gene therapy manufacturing services market is segmented into cell therapy and gene therapy. Cell therapy is segmented as autologous and allogenic. Further, gene therapy is bifurcated into viral vector and non-viral vector. The cell therapy segment held a larger market share in 2022. However, gene therapy segment is anticipated to register the highest CAGR of 16.6% during the forecast period (2022-2030). Gene therapy is a technique that uses a gene(s) to prevent, treat or cure a medical disorder or disease. Gene therapies often works by replacing a defective, or by adding new copies of a gene that is broken or missing gene in a patient’s cells with a healthy version of that gene. Gene therapy can be used to modify cells outside as well as inside the body. A vector is injected carrying the gene directly into the patient when a gene therapy is used to modify cells inside the body. Whereas blood, bone marrow, or another tissue are taken out when gene therapy is used to modify cells outside the body and separate the specific cell types in the lab.
Cell and Gene Therapy Manufacturing Services Market, by Region, 2022(%)
Cell and Gene Therapy Manufacturing Services Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type [Cell Therapy (Autologous and Allogenic) and Gene Therapy (Viral and Non-Viral Vector)], Indication (Cancer, Orthopaedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), End User [Pharmaceutical and Biotechnology Companies and Contract Research Organization (CROs)], and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Cell and Gene Therapy Manufacturing Services Market Report | 2022–2030
Download Free Sample
Source: The Insight Partners Analysis
Thermo Fisher Scientific Inc, Merck KGaA, Charles River Laboratories International Inc, Lonza Group AG, WuXi AppTec Co Ltd, Catalent Inc, Takara Bio Inc, Nikon Corp, FUJIFILM Holdings Corp, National Resilience Inc, and Oxford BioMedica Plc are among the leading companies operating in the cell and gene therapy manufacturing services market.
Based on type, the cell and gene therapy manufacturing services market is segmented into cell therapy and gene therapy. In terms of indication, the cell and gene therapy manufacturing services market is segmented into cancer, orthopaedics, and others. By application, the cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In terms of end user, the cell and gene therapy manufacturing services market is segmented into pharmaceutical and biotechnology companies and contract research organization (CROs). By country, the cell and gene therapy manufacturing services market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com